Hi folks, thanks for listening to Patient Zero. This week we're doing something a little different.

Instead of a full episode, you're getting one of several bonus episodes that up until now have only been available to donors of New Hampshire Public Radio.

We wanted you to hear this one for three reasons.

One, because you deserve to know how awesome our bonus episodes are.

Two, because the topic addressed in this episode is one that a lot of people who haven't donated have asked about.

It's important.

And three, because I needed a couple extra days to finish the next full episodes.

The show is a lot of work and we're committed to doing the best and most thorough job possible.

So thanks for listening and if you dig this bonus episode check out the others by making a donation of $20.

There's a link in the northeast, Lyme disease scares people.

It scares them so much. I've heard parents talking about not letting their kids go out in the woods.

I heard a woman once waffle over whether her

grandkids should be allowed in their backyard. People want some kind, any kind of

protection. One of the questions that I am asked almost more than anything else. Why can my dog

be vaccinated against Lyme disease but I can't? Why can't they come up with a human

version? And of course the answer is we have a human

version or we had a human version. Megan May teaches about infectious disease at

the University of New England and she's here to tell

us the story of Limerix.

Limerix is the vaccine developed by the giant multinational pharmaceutical company, GlaxoSmith Kleinline that was released in 1998 but pulled from the market in 2002.

The development of Limerix was a really interesting point in in vaccine technology because it was among the first

human vaccines that was approved for use that was completely synthetic.

...